Femtosecond laser systems superior to microkeratome system
Flap creation for bilateral LASIK is best performed using an IntraLase, VisuMax or Femto LDV, rather than a microkeratome.
An investigation featured in the Journal of Cataract and Refractive Surgery shows flap creation for bilateral LASIK is best performed using an IntraLase, VisuMax or Femto LDV, rather than a microkeratome.
A team led by Dr Hyunseok Ahn, Department of Ophthalmology, Institute of Vision and Research, Yonsei University College of Medicine, Seoul, South Korea, evaluated the thickness and side-cut angle of LASIK flaps made by 1 of 3 femtosecond lasers or an M2 microkeratome, using a RtVue Fourier–domain OCT.
The participants were split into 3 femtosecond laser groups and 1 microkeratome group. Femtosecond laser group 1 (Intralase) consisted of 50 eyes, group 2, 40 eyes (VisuMax), group 3, 64 eyes (Femto LDV) and the microkeratome group consisted of 52 eyes. Groups 1 and 2 had fairly even flap configuration. Group 3 and 4 had a meniscus shape, with group 3 having the greatest flap thickness predictability.
All three of the femtosecond laser systems performed better than the microkeratome system in general. The IntraLase's side-cut angle was closest to 90º and had the least difference between central flap thickness and the mean peripeheral. The femtosecond laser systems were also able to produce a variety of flap configurations depending on the each mechanism.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
